News | Proton Therapy | September 25, 2020

Important milestone demonstrates the unrivaled experience, technological innovation and global market leadership of IBA and its clinical partners

Important milestone demonstrates the unrivalled experience, technological innovation and global market leadership of IBA and its clinical partners

September 25, 2020 — IBA (Ion Beam Applications SA) announced that more than 100,000 patients have now been treated with IBA proton therapy systems around the world. This is an important milestone that marks a step towards IBA’s mission to make proton therapy available to all patients who could benefit from it, by providing healthcare professionals with the most advanced, high performance proton therapy solutions. This milestone is a proud moment for IBA’s employees and clinical partners around the world as they remain united in their efforts to maximize the positive impact on cancer patients’ lives.

Olivier Legrain, Chief Executive Officer at IBA, commented: “We are immensely proud that IBA’s technology has impacted 100,000 lives, giving patients and their families a new hope for the future. Reaching this milestone would not have been possible without the commitment of our employees and the close relationships that we have continued to build with our clients and partners over the last 30 years. Our common goal is to make proton therapy accessible to a greater number of patients, and we believe that our passion, energy and expertise will enable us to achieve this. We continue to pursue further innovation by developing new technologies that will allow us to provide increasingly high standards while reducing treatment costs. I would like to offer my warmest thanks to our partners and employees for their efforts to protect, enhance and save lives.” 

Proton therapy is one of the most promising forms of cancer therapy and is considered the most advanced form of radiotherapy in cancer treatments. Proton therapy makes it possible to target tumors with better precision, minimizing radiation exposure of the surrounding healthy tissue and thereby improving the quality of life of patients during and after treatment.

The clinical benefits of proton therapy are increasingly acknowledged. As the number of patients being treated with proton therapy continues to grow, appreciation of the effectiveness of the technology is also increasing within the medical community. A large number of clinical studies are currently ongoing and their results have the potential to open a new era for proton therapy treatment.

Proton therapy is becoming more and more accessible to a growing number of patients throughout the world. IBA has invested substantial resources in researching and developing new approaches to minimize the cost of proton therapy and make it more accessible to the maximum number of cancer patients. IBA’s Proteus ONE compact single room solution is game changing with regard to making the treatment more accessible, whilst retaining the latest technological capabilities in proton therapy.

IBA continues to invest in the research and development of innovative technological solutions to further advance its proton therapy offering. The technological roadmap of IBA is focused on three areas: Motion Management, Arc Therapy and FLASH Irradiation. IBA constantly looks to improve the proton therapy technology for the benefit of patients, in close collaboration with its customers and industrial partners.

The largest and most experienced proton therapy community. With 36 centers treating patients in 86 rooms, and another 20 centers in development, IBA’s user community is unrivalled. This unique experience from IBA clinical partners coupled with IBA’s unique technological expertise and open partnership philosophy ideally positions the company to continue to lead innovation in proton therapy.

For more information: www.iba-worldwide.com

Related Content

News | Ultrasound Women's Health

October 14, 2021 — In a first-in-world clinical trial, researchers at Sunnybrook Health Sciences Centre in Toronto ...

Time October 14, 2021
arrow
News | Lung Imaging

October 11, 2021 — According to ARRS’ American Journal of Roentgenology (AJR), percutaneous image-guided microwave and ...

Time October 11, 2021
arrow
News | Women's Health

October 8, 2021 — An analysis of nearly 200,000 patients who received mammograms between 2006 and 2015 across three U.S ...

Time October 08, 2021
arrow
News | Radiation Therapy

October 7, 2021 — NANOBIOTIX, a late-stage clinical biotechnology company pioneering physics-based approaches to expand ...

Time October 07, 2021
arrow
News | Radiation Therapy

October 7, 2021 — ViewRay, Inc. announced that the company has received acceptance from the FDA on their recent ...

Time October 07, 2021
arrow
News | Women's Health

October 5, 2021 — A promising radionuclide treatment may offer new therapeutic options for breast cancer patients ...

Time October 05, 2021
arrow
Feature | Radiation Therapy | By Dave Fornell

To maintain safety in radiation therapy (RT), every machine performance and patient delivery measurement must be as ...

Time October 05, 2021
arrow
News | Radiation Oncology

September 28, 2021 — The global radiotherapy devices market is expected to grow from $5.44 billion in 2020 to $5.848 ...

Time September 28, 2021
arrow
News | Prostate Cancer

September 24, 2021 — Scientists have identified two subtypes of metastatic prostate cancer that respond differently to ...

Time September 24, 2021
arrow
News | Artificial Intelligence

September 24, 2021 — Owkin, a startup that deploys artificial intelligence (AI) and Federated Learning technologies to ...

Time September 24, 2021
arrow
Subscribe Now